Roche News | finanzen.ch

Roche Aktie VALOR 1203211 / ISIN CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

23.03.21	Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency (GlobeNewswire)
23.03.21	New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 (GlobeNewswire)
22.03.21	Roche provides update on tominersen programme in manifest Huntington’s disease (GlobeNewswire)
22.03.21	Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning (GlobeNewswire)
17.03.21	Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs (GlobeNewswire)
16.03.21	Roche Annual General Meeting 2021 (GlobeNewswire)
16.03.21	Roche Generalversammlung 2021 (GlobeNewswire)
16.03.21	Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations (GlobeNewswire)
16.03.21	New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) (GlobeNewswire)
15.03.21	Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample (GlobeNewswire)
11.03.21	Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems (GlobeNewswire)
11.03.21	Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia (GlobeNewswire)
08.03.21	Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer (GlobeNewswire)
05.03.21	Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung di (GlobeNewswire)
26.02.21	Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany (GlobeNewswire)
26.02.21	EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 (GlobeNewswire)
26.02.21	Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older (GlobeNewswire)
25.02.21	Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine (GlobeNewswire)
12.02.21	New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially red (GlobeNewswire)
08.02.21	FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weig (GlobeNewswire)
04.02.21	Roche reports solid results in 2020 (GlobeNewswire)
04.02.21	Roche mit solidem Jahresergebnis für 2020 (GlobeNewswire)
01.02.21	Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection (GlobeNewswire)
25.01.21	Roche renews partnership with Sysmex to deliver haematology testing solutions (GlobeNewswire)
25.01.21	Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degenerati (GlobeNewswire)
18.01.21	Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy (GlobeNewswire)
18.01.21	Ordentliche Roche Generalversammlung 2021: Abstimmungen und Wahlen durch die unabhängige Stimmrechtsvertreterin (GlobeNewswire)
12.01.21	Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab (GlobeNewswire)
12.01.21	Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer (GlobeNewswire)
11.01.21	Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer (GlobeNewswire)
11.01.21	Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years (GlobeNewswire)
05.01.21	Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer (GlobeNewswire)
23.12.20	European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer (GlobeNewswire)
21.12.20	Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness (GlobeNewswire)
15.12.20	Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark (GlobeNewswire)
14.12.20	FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis (GlobeNewswire)
11.12.20	Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients (GlobeNewswire)
10.12.20	Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 (GlobeNewswire)
09.12.20	Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials (GlobeNewswire)
08.12.20	Roche presents new data from its bispecific antibody portfolio across a range of blood cancers (GlobeNewswire)
07.12.20	New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
07.12.20	New follow-up phase III data reinforce the long-term benefit of Roche’s Hemlibra for people with haemophilia A (GlobeNewswire)
05.12.20	Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia (GlobeNewswire)
02.12.20	Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers (GlobeNewswire)
02.12.20	Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies (GlobeNewswire)
01.12.20	FDA approves Xolair® (omalizumab) for adults with nasal polyps (GlobeNewswire)
24.11.20	Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person (GlobeNewswire)
16.11.20	Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh time (GlobeNewswire)
16.11.20	Roche zum elften Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
13.11.20	CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer